NO20006381L - Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretion agents - Google Patents
Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretion agentsInfo
- Publication number
- NO20006381L NO20006381L NO20006381A NO20006381A NO20006381L NO 20006381 L NO20006381 L NO 20006381L NO 20006381 A NO20006381 A NO 20006381A NO 20006381 A NO20006381 A NO 20006381A NO 20006381 L NO20006381 L NO 20006381L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- serm
- selective
- growth hormone
- estrogen receptor
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title 1
- 108010051696 Growth Hormone Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000002834 estrogen receptor modulator Substances 0.000 title 1
- 239000000122 growth hormone Substances 0.000 title 1
- 230000028327 secretion Effects 0.000 title 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 title 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 4- (2-pyrrolidin-1-yl-ethoxy) -phenyl Chemical group 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Det er beskrevet farmasøytiske kombinasjonssammensetninger og fremgangsmåter omfattende (-)-cis-6-fenyl-5-(4-(2-pyrrolidin-1 -yl-etoksy)-fenyl)-S.ej.S-tetrahydronaftalen^-ol eller et farmasøytiskakseptabelt salt derav og 2-amino-N-(1(RH2,4-difluor-benzyloksymetyl)-2okso-2-(3-okso-3a(R)-pyirdin-2-yl-metyl^^^^-tnfluortyl^.a.aa^.ej-heksahydro-pyrazol^^cjpyridin-S-yl)-etyl)-2-metyl-propionamid eller et farmasøytisk akseptabelt salt derav, fremgangsmåter for anvendelse.av slike sammensetninger og settinneholdende slike. sammensetninger. Sammensetningene er nyttige for behandling av muskel-skjelettsvakhet, inkludert osteoporose, osteoporotiske brudd, lav benmasse, skjørhet og lav muskelmasse.Pharmaceutical combination compositions and methods are described comprising (-) - cis-6-phenyl-5- (4- (2-pyrrolidin-1-yl-ethoxy) -phenyl) -S.ej.S-tetrahydronaphthalen Pharmaceutically acceptable salt thereof and 2-amino-N- (1 (RH2,4-difluoro-benzyloxymethyl) -2-oxo-2- (3-oxo-3a (R) -pyridin-2-yl-methyl] (aa) -hexahydro-pyrazol (c-pyridin-5-yl) -ethyl) -2-methyl-propionamide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kit-containing ones. compositions. The compositions are useful for the treatment of musculoskeletal weakness, including osteoporosis, osteoporotic fractures, low bone mass, fragility and low muscle mass.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 | |
| PCT/IB1999/000796 WO1999065488A1 (en) | 1998-06-16 | 1999-05-03 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006381L true NO20006381L (en) | 2000-12-14 |
| NO20006381D0 NO20006381D0 (en) | 2000-12-14 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006381A NO20006381D0 (en) | 1998-06-16 | 2000-12-14 | Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretion agents |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (en) |
| JP (1) | JP2002518328A (en) |
| KR (1) | KR20010052817A (en) |
| CN (1) | CN1305378A (en) |
| AP (1) | AP9901581A0 (en) |
| AR (1) | AR018868A1 (en) |
| AU (1) | AU3342099A (en) |
| BG (1) | BG105128A (en) |
| BR (1) | BR9911357A (en) |
| CA (1) | CA2335112A1 (en) |
| CO (1) | CO5070586A1 (en) |
| EA (1) | EA200001189A1 (en) |
| GT (1) | GT199900083A (en) |
| HR (1) | HRP20000857A2 (en) |
| HU (1) | HUP0102395A2 (en) |
| ID (1) | ID26726A (en) |
| IL (1) | IL139587A0 (en) |
| IS (1) | IS5727A (en) |
| MA (1) | MA26648A1 (en) |
| NO (1) | NO20006381D0 (en) |
| OA (1) | OA11569A (en) |
| PA (1) | PA8472101A1 (en) |
| PE (1) | PE20000633A1 (en) |
| PL (1) | PL345064A1 (en) |
| SK (1) | SK18902000A3 (en) |
| TN (1) | TNSN99118A1 (en) |
| UY (1) | UY25557A1 (en) |
| WO (1) | WO1999065488A1 (en) |
| ZA (1) | ZA993973B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| MXPA04005112A (en) * | 2001-11-29 | 2005-04-29 | Gtx Inc | Prevention and treatment of androgen-deprivation induced osteoporosis. |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| KR20090107088A (en) | 2007-02-09 | 2009-10-12 | 트랜자임 파르마 인크 | Macrocyclic ghrelin receptor modulators and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/en active Pending
- 1999-05-03 PL PL99345064A patent/PL345064A1/en unknown
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/en not_active Ceased
- 1999-05-03 IL IL13958799A patent/IL139587A0/en unknown
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/en unknown
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/en not_active Application Discontinuation
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/en unknown
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Ceased
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 ID IDW20002604A patent/ID26726A/en unknown
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 HR HR20000857A patent/HRP20000857A2/en not_active Application Discontinuation
- 1999-05-03 CN CN99807381A patent/CN1305378A/en active Pending
- 1999-05-03 EA EA200001189A patent/EA200001189A1/en unknown
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/en unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/en not_active Application Discontinuation
- 1999-06-11 UY UY25557A patent/UY25557A1/en not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/en unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/en unknown
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/en unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/en not_active Application Discontinuation
- 1999-06-15 MA MA25622A patent/MA26648A1/en unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/en unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/en unknown
- 2000-12-14 NO NO20006381A patent/NO20006381D0/en not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8472101A1 (en) | 2000-09-29 |
| IS5727A (en) | 2000-11-24 |
| GT199900083A (en) | 2000-12-05 |
| CN1305378A (en) | 2001-07-25 |
| WO1999065488A1 (en) | 1999-12-23 |
| HRP20000857A2 (en) | 2001-10-31 |
| AP9901581A0 (en) | 1999-06-30 |
| ZA993973B (en) | 2000-12-15 |
| HUP0102395A2 (en) | 2001-11-28 |
| UY25557A1 (en) | 2001-01-31 |
| IL139587A0 (en) | 2002-02-10 |
| SK18902000A3 (en) | 2001-12-03 |
| AU3342099A (en) | 2000-01-05 |
| AR018868A1 (en) | 2001-12-12 |
| EP1085867A1 (en) | 2001-03-28 |
| BR9911357A (en) | 2001-03-13 |
| PE20000633A1 (en) | 2000-07-26 |
| EA200001189A1 (en) | 2001-06-25 |
| MA26648A1 (en) | 2004-12-20 |
| OA11569A (en) | 2004-07-01 |
| PL345064A1 (en) | 2001-11-19 |
| JP2002518328A (en) | 2002-06-25 |
| TNSN99118A1 (en) | 2005-11-10 |
| BG105128A (en) | 2001-11-30 |
| CO5070586A1 (en) | 2001-08-28 |
| ID26726A (en) | 2001-02-01 |
| NO20006381D0 (en) | 2000-12-14 |
| CA2335112A1 (en) | 1999-12-23 |
| KR20010052817A (en) | 2001-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001258138A1 (en) | Bone plate for the fixation of fractures of the proximal humerus | |
| SI1389963T1 (en) | Bone plate for the fixation of fractures of the proximal humerus | |
| YU18400A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| EP1236475A3 (en) | Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue | |
| AU651369B2 (en) | Method and apparatus for the fixation of bone fractures, limb lengthening and the correction of deformities | |
| EA200600228A1 (en) | TREATMENT OF BONE TISSUE DISTURBANCES WITH THE USE OF SELECTIVE MODULATORS OF ADROGENIC RECEPTORS | |
| NO951498L (en) | Pharmaceutical preparation for the treatment of osteoporosis | |
| NO20006381L (en) | Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretion agents | |
| DK0937478T3 (en) | Device and apparatus for intracavitary administration of drugs during video-assisted surgery or other endoscopic procedure | |
| WO2001043733A3 (en) | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | |
| BG105125A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| ID18079A (en) | PHARMACEUTICAL COMPOSITION THAT CONTAINS FASTEST OSTEOGENESIS | |
| NO20040598L (en) | 5-CNAC as an oral delivery agent for parathyroid hormone fragments. | |
| NO20006312L (en) | Therapeutic mixtures of selective estrogen receptor modulators (SERMs) and growth hormone secretion stimulants (GHS) for the treatment of musculoskeletal fragility | |
| NO991589D0 (en) | Novel 3-, 5- and / or 6-substituted analogues of swainsonine, methods for their preparation and their use as therapeutic agents | |
| DK0966968T3 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2 | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| WO2001032191A3 (en) | Phytoestrogenic pharmaceutical preparations | |
| ECSP993016A (en) | THERAPEUTIC COMBINATIONS INCLUDING A SELECTIVE ESTROGEN RECEPTOR AND PARATOROID HORMONE MODULATOR | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| AU2001265248A1 (en) | Measurement of the therapeutic dose for bone marrow ablation therapy | |
| DK1090027T3 (en) | New 17-Halogenated 19-Nor Steroids, Processes for their Preparation, Intermediates, Their Use as Drugs and Pharmaceutical Preparations Containing them | |
| TH57984A3 (en) | A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone. | |
| RU2003125500A (en) | A method for the treatment of fractures of the proximal femur with a separation of the lesser trochanter with coxarthrosis | |
| TH48282A (en) | Treatment of diseases of the drug combination of osteoporosis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |